Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer Life Science Investing
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules Life Science Investing
iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026 Life Science Investing
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update Life Science Investing
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® INJECTION AND LAUNCH OF NEW BRAND WEBSITE Life Science Investing
Profound Medical to Release First Quarter 2026 Financial Results on May 7 - Conference Call to Follow Life Science Investing
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting Life Science Investing
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery Life Science Investing
